AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013

AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference
                       Call and Webcast on May 8, 2013

PR Newswire

REDWOOD CITY, Calif., May 3, 2013

REDWOOD CITY, Calif., May 3, 2013 /PRNewswire/ --AcelRx Pharmaceuticals, Inc.
(Nasdaq: ACRX), a specialty pharmaceutical company focused on the development
and commercialization of innovative therapies for the treatment of acute and
breakthrough pain, today announced that it will release first quarter 2013
financial results after market close on Wednesday, May 8, 2013. AcelRx
management will host an investment-community conference call at 4:30 p.m.
Eastern time (1:30 p.m. Pacific time) on May 8, 2013 to discuss the financial
results and provide a corporate update.

Investors who wish to participate in the conference call may do so by dialing
(800) 860-2442 for domestic callers, (866) 605-3852 for Canadian callers or
(412) 858-4600 for international callers. Those interested in listening to the
conference call live via the Internet may do so by visiting the Investors page
of the company's website at www.acelrx.com and clicking on the webcast link in
the Event Calendar page.

A webcast replay will be available on the AcelRx website for 90 days following
the call by visiting the Investors page of the company's website at
www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain. AcelRx's lead product candidate, the
Sufentanil NanoTab PCA System, or NanoTab System, is designed to solve the
problems associated with post-operative intravenous patient-controlled
analgesia which has been shown to cause harm to patients following surgery
because of the side effects of morphine, the invasive IV route of delivery and
the complexity of infusion pumps. AcelRx has announced results from two Phase
3 clinical trials for the NanoTab System, and a third Phase 3 study has
completed enrollment, with data expected in the second quarter of 2013. A New
Drug Application submission is planned for the third quarter of 2013. AcelRx
recently announced positive top-line results for a Phase 2 trial for ARX-04, a
sufentanil formulation for the treatment of moderate-to-severe acute pain,
funded through a grant from USAMRMC. The company has two additional pain
treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2
clinical development. For additional information about AcelRx's clinical
programs please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not
limited to, statements related to the release and anticipated timing of
additional NanoTab System clinical trial data, anticipated timing of
completion of AcelRx Pharmaceuticals' current clinical trials, submission of
the NDA, and the therapeutic potential of AcelRx Pharmaceuticals' product
candidates.These forward-looking statements are based on AcelRx
Pharmaceuticals' current expectations and inherently involve significant risks
and uncertainties. AcelRx Pharmaceuticals' actual results and the timing of
events could differ materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which include,
without limitation, risks related to: the success, cost and timing of AcelRx
Pharmaceuticals' product development activities and clinical trials; its
ability to obtain sufficient financing to complete development and
registration of its product candidates in the United States and Europe; its
ability to obtain and maintain regulatory approvals of its product candidates;
the market potential for its product candidates; and other risks detailed in
the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities
and Exchange Commission filings, including its Annual Report on Form 10-K
filed with the SEC on March 12, 2013. AcelRx Pharmaceuticals undertakes no
duty or obligation to update any forward-looking statements contained in this
release as a result of new information, future events or changes in its
expectations.

(Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)

SOURCE AcelRx Pharmaceuticals, Inc.

Website: http://www.acelrx.com
Contact: Jim Welch, Chief Financial Officer, 650.216.3511, jwelch@acelrx.com
 
Press spacebar to pause and continue. Press esc to stop.